Acelyrin, Inc.
SLRN · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | -$0 | -$0 |
| % Margin | – | 50% | – | – |
| R&D Expenses | $42 | $72 | $32 | $76 |
| G&A Expenses | $18 | $13 | $12 | $17 |
| SG&A Expenses | $18 | $13 | $12 | $17 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $1 | $11 | $0 |
| Operating Expenses | $60 | $86 | $55 | $93 |
| Operating Income | -$60 | -$86 | -$55 | -$93 |
| % Margin | – | -25,062% | – | – |
| Other Income/Exp. Net | $5 | $7 | $6 | $7 |
| Pre-Tax Income | -$55 | -$79 | -$49 | -$86 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$55 | -$79 | -$49 | -$86 |
| % Margin | – | -23,109.1% | – | – |
| EPS | -0.55 | -0.8 | -0.49 | -0.86 |
| % Growth | 31.3% | -63.3% | 43% | – |
| EPS Diluted | -0.55 | -0.8 | -0.49 | -0.86 |
| Weighted Avg Shares Out | 101 | 99 | 100 | 99 |
| Weighted Avg Shares Out Dil | 101 | 99 | 100 | 99 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $6 | $8 | $8 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$60 | -$28 | -$44 | -$93 |
| % Margin | – | -8,287.4% | – | – |